BioIVT will contribute its assay development and validation expertise to support the consortium’s research initiatives
Westbury, NY – Mar. 25, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.
The FNIH Biomarkers Consortium is a public-private biomedical research partnership. It brings together members of industry, academia, nonprofit and patient advocacy organizations, and government agencies and institutes to develop and support research to qualify promising biomarkers for diagnosing disease, predicting therapeutic response or improving clinical practice.
“We’re proud to contribute our research expertise to support the FNIH Biomarkers Consortium programs. Our research services groups will be able to assist in the development of new assays supporting diagnostic, efficacy and safety biomarker research for cancer, metabolic disorders, neuroscience, and inflammation and immunity applications,” said Amanda Woodrooffe, PhD, vice president and general manager, PHASEZERO® Research Services at BioIVT.
“We are excited to welcome BioIVT as the newest member of the FNIH Biomarkers Consortium. BioIVT’s expertise and commitment to scientific discovery will help us accelerate biomedical research to fight diseases across the world,” said Joseph P. Menetski, PhD, associate vice president for research partnerships, the FNIH.
BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.
About the Foundation for the National Institutes of Health
The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The Foundation, also known as the FNIH, works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit fnih.org.
Phone: (206) 992-5245